Aridis Pharmaceuticals Inc (ARDS)

NASDAQ
0.970
+0.100(+11.49%)
  • Volume:
    7,658
  • Day's Range:
    0.880 - 0.983
  • 52 wk Range:
    0.683 - 4.340

ARDS Overview

Prev. Close
0.9
Day's Range
0.88-0.983
Revenue
2.87M
Open
0.88
52 wk Range
0.683-4.34
EPS
-1.92
Volume
7,658
Market Cap
17.16M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
139,539
P/E Ratio
-0.469
Beta
1.41
1-Year Change
-61.37%
Shares Outstanding
19,501,592
Next Earnings Date
Mar 30, 2023
What is your sentiment on Aridis Pharma?
or
Vote to see community's results!

Aridis Pharmaceuticals Inc News

Aridis Pharmaceuticals Inc Analysis

Aridis Pharmaceuticals Inc Company Profile

Aridis Pharmaceuticals Inc Company Profile

Employees
34

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

Read More

Analyst Price Target

Average10.500 (+982.47% Upside)
High19
Low2
Price0.97
No. of Analysts3
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellStrong SellStrong Sell
Technical IndicatorsSellSellStrong SellBuyStrong Sell
SummaryStrong SellStrong SellStrong SellNeutralStrong Sell